findmyKOL
Clinical trialNCT06922539RecruitingPhase 1Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SponsorSciTech Development, Inc.Enrollment44Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Southern California

    Los Angeles, California, United States

    Jacob S Thomas, M.D.
    Recruiting
  • Henry Ford Cancer Institute

    Detroit, Michigan, United States

    Bindu R Potugari, M.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FENRETINIDE
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Dec 2025
Primary completion
1 May 2027
Completion
1 Oct 2028
Last update posted
19 Aug 2026
Registered enrollment
44
Registry id
NCT06922539
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.